PRE-FUNDED COMMON STOCK PURCHASE WARRANT ADAMIS PHARMACEUTICALS CORPORATIONAdamis Pharmaceuticals Corp • July 13th, 2023 • Pharmaceutical preparations
THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from Adamis Pharmaceuticals Corporation, a corporation incorporated under the laws of the state of Delaware (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
EQUINITI TRUST COMPANY, LLC, as Warrant Agent Warrant Agency Agreement Dated as of July __, 2023 WARRANT AGENCY AGREEMENTWarrant Agency Agreement • July 13th, 2023 • Adamis Pharmaceuticals Corp • Pharmaceutical preparations • New York
WARRANT AGENCY AGREEMENT, dated as of July ___, 2023 (“Agreement”), between Adamis Pharmaceuticals Corporation, a corporation organized under the laws of the State of Delaware (the “Company”), and Equiniti Trust Company, LLC (the “Warrant Agent”).
COMMON STOCK PURCHASE WARRANT ADAMIS PHARMACEUTICALS CORPORATIONAdamis Pharmaceuticals Corp • July 13th, 2023 • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [_______] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after July ___, 2023 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on July ___, 2028 (the “Termination Date”), but not thereafter, to subscribe for and purchase from Adamis Pharmaceuticals Corporation, a Delaware corporation (the “Company”), up to _______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant shall initially be issued and maintained in the form of a security held in book-entry form and the Depository Trust Company or its nominee (“DTC”) shall initially be the sole registered holder of this Warrant, subject to a
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • July 13th, 2023 • Adamis Pharmaceuticals Corp • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of [___], 2023, and is between Adamis Pharmaceuticals Corporation, a corporation incorporated under the laws of the state of Delaware (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
Adamis Pharmaceuticals Corporation S-1Adamis Pharmaceuticals Corp • July 13th, 2023 • Pharmaceutical preparations • New York
This letter (the “Agreement”) constitutes the agreement between Maxim Group LLC (the “Placement Agent”) and Adamis Pharmaceuticals Corporation, a Delaware corporation (the “Company”), that the Placement Agent shall serve as the exclusive placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) to certain purchasers (the “Purchasers”) of up to an aggregate of (i) [___] common units (each a “Common Unit” and collectively, the “Common Units”), with each Common Unit consisting of (A) one share (each a “Share” and collectively, the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), (B) one common stock purchase warrant (each a “Warrant” and collectively, the “Warrants”) to purchase one share of Common Stock (the “Warrant Shares”) exercisable immediately and expiring five years after the date of issuance at an exercise price of $[__] per share of Common Stock, and (ii) [____] pre
